{"id":"b396b6f3-0a61-511d-b7bd-08a0d7452574","stable_key":"a9dd23c6-978a-5755-8bd8-f29bd1fe0cda:nia-clin-aimhigh-events","predicate":"does_not_reduce_in_tested_regimen","statement":"The AIM-HIGH composite endpoint occurred in 16.4% versus 16.2% of niacin and placebo participants: hazard ratio 1.02, 95% CI 0.87–1.21.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"db81e1df-3401-54d9-bc6a-be6ac10fc996","mechanism_event_label":"Improved lipid numbers did not translate into fewer trial cardiovascular events in these statin-treated patients.","subject":{"id":"9751fdb6-9b30-586f-b07a-79b8e2cd62dd","slug":"nicotinic-acid","display_name":"Nicotinic acid","entity_type_key":"small_molecule"},"object":{"id":"8f08bd23-f5e8-5787-b7b5-d6e1e26ed99c","slug":"major-cardiovascular-event-incidence","display_name":"Major cardiovascular event incidence","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"db81e1df-3401-54d9-bc6a-be6ac10fc996","stable_key":"a9dd23c6-978a-5755-8bd8-f29bd1fe0cda:nia-clin-aimhigh-events-event","event_type":"observed_intervention","label":"Improved lipid numbers did not translate into fewer trial cardiovascular events in these statin-treated patients.","description":"The AIM-HIGH composite endpoint occurred in 16.4% versus 16.2% of niacin and placebo participants: hazard ratio 1.02, 95% CI 0.87–1.21.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"9751fdb6-9b30-586f-b07a-79b8e2cd62dd","slug":"nicotinic-acid","display_name":"Nicotinic acid","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"8f08bd23-f5e8-5787-b7b5-d6e1e26ed99c","slug":"major-cardiovascular-event-incidence","display_name":"Major cardiovascular event incidence","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"cross_nutrient","value_text":"Niacin precursor form and the measured endpoint are separate graph entities.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/niacin-clinical-sources/aimhigh2011.abstract.txt\", \"locator\": \"Indexed primary abstract\", \"file_sha256\": \"eefcc0d7eed5694eb9d1861a06fc5a256986753607c2095996304fd0de25f3aa\", \"start_char\": 0, \"end_char\": 2340, \"text_sha256\": \"eefcc0d7eed5694eb9d1861a06fc5a256986753607c2095996304fd0de25f3aa\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"AIM-HIGH randomized trial; 3,414 patients with established cardiovascular disease on intensive statin therapy","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Extended-release nicotinic acid 1,500–2,000 mg/day versus placebo; mean 3-year follow-up","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Pharmacological dosing added to statin therapy. Lipid changes are not equivalent to clinical benefit. Trial stopped for lack of efficacy; no inference about treating dietary niacin deficiency.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Niacin research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"niacin","display_name":"Niacin (vitamin B3)","entity_type_key":"nutrient_element"}},{"dimension":"organism","value_text":"Homo sapiens","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Improved lipid numbers did not translate into fewer trial cardiovascular events in these statin-treated patients.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[nia-clin-aimhigh2011] Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. (2011). https://pubmed.ncbi.nlm.nih.gov/22085343/ DOI: 10.1056/nejmoa1107579","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Circulating lipids and cardiovascular outcomes","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"aa905caa-3ee1-5fb6-a4ea-92163118934f","evidence_kind":"source_excerpt","locator":"Lines 1389-1401","start_line":1389,"end_line":1401,"excerpt":"### nia-clin-aimhigh-events\nThe AIM-HIGH composite endpoint occurred in 16.4% versus 16.2% of niacin and placebo participants: hazard ratio 1.02, 95% CI 0.87–1.21.\nCondition category: normal\nnutrient_topic: Niacin research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: Improved lipid numbers did not translate into fewer trial cardiovascular events in these statin-treated patients.\norganism: Homo sapiens\ntissue_or_cell_type: Circulating lipids and cardiovascular outcomes\nexperimental_model: AIM-HIGH randomized trial; 3,414 patients with established cardiovascular disease on intensive statin therapy\nlimitations: Pharmacological dosing added to statin therapy. Lipid changes are not equivalent to clinical benefit. Trial stopped for lack of efficacy; no inference about treating dietary niacin deficiency.\nexposure: Extended-release nicotinic acid 1,500–2,000 mg/day versus placebo; mean 3-year follow-up\ncross_nutrient: Niacin precursor form and the measured endpoint are separate graph entities.\nevidence_span: {\"source_cache\": \"artifacts/niacin-clinical-sources/aimhigh2011.abstract.txt\", \"locator\": \"Indexed primary abstract\", \"file_sha256\": \"eefcc0d7eed5694eb9d1861a06fc5a256986753607c2095996304fd0de25f3aa\", \"start_char\": 0, \"end_char\": 2340, \"text_sha256\": \"eefcc0d7eed5694eb9d1861a06fc5a256986753607c2095996304fd0de25f3aa\"}\n[nia-clin-aimhigh2011] Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. (2011). https://pubmed.ncbi.nlm.nih.gov/22085343/ DOI: 10.1056/nejmoa1107579","model_system":"AIM-HIGH randomized trial; 3,414 patients with established cardiovascular disease on intensive statin therapy","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [nia-clin-aimhigh2011] Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. (2011). https://pubmed.ncbi.nlm.nih.gov/22085343/ DOI: 10.1056/nejmoa1107579","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"a62b7b5b-786a-57e9-85e9-67c6912a5054","stable_key":"import-a9dd23c6-978a-5755-8bd8-f29bd1fe0cda","title":"Niacin: NAD metabolism, deficiency and nutrient interactions (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"a8cac59639322f74812ce12eef338c2f6c385c04cc4af6ab511fc7c972f0c2e6","revision_id":"bec8fc45-12e7-5f75-a814-5d72ed015d01","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}